In postmortem brain material of preclinical Parkinson’s disease (PD), clinical PD, and control subjects, we determined with quantitative in situ hybridization and immunocytochemistry the expression of histidine decarboxylase (HDC)-mRNA, the key enzyme of histamine production, and the amount of Lewy bodies/Lewy neuritis (LBs/LNs), the pathology markers of PD, in the hypothalamic tuberomammillary nucleus (TMN). No significant difference of HDC-mRNA levels was observed either in the preclinical or in the clinical PD patients, in spite of the strong accumulation of LBs/LNs in the TMN of clinical PD. These findings indicated that the neuronal histamine production remains largely unaltered in PD, and that the pathological alteration of PD may rather protect the TMN from degeneration instead of causing degeneration. This study provides new ideas for studying PD pathogenesis. The paper was published in Neurobiology of Aging.
Over recent decades, A. baumannii has emerged as a major global hospital-acquired pathogen. Bloodstream infections (BSIs) caused by this bacterium carry a mortality rate of up to 60% and imp...
SAHZU Neurologist Prof. LOU Min and her team recently found that, despite an increased risk of symptomatic intracranial hemorrhage, intravenous alteplase provided functional benefit to acute ischemic ...
The genome, made up of DNA, contains not only protein-coding sequences but also a vast array of non-coding regulatory sequences. These two types of sequence work in concert to shape the complex phenot...
